Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

Author(s):

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago

Although the NCCN guidelines recommend osimertinib as an adjuvant therapy option, what is your position on its use for completely resected stage IB to IIIA NSCLC with less common EGFR activating mutations, such as exon 20 insertion?

EP: 1.Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

EP: 2.Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

EP: 3.ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

Now Viewing

EP: 4.Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

Video content above is prompted by the following:

Although the NCCN guidelines recommend osimertinib as an adjuvant therapy option, what is your position on its use for completely resected stage IB to IIIA NSCLC with less common EGFR activating mutations, such as exon 20 insertion?